WSPR Szczecin Taps ZOLL AutoPulse

Resuscitation devices maker ZOLL Medical (ZOLL) said that its new AutoPulse Plus cardiac support pumps has been bought by WSPR Szczecin, the biggest emergency service operator in Poland. The Polish entity has purchased 49 such devices to equip its fleet of ambulances.

The innovative AutoPulse Plus pumps enables rescuers to defibrillate without stopping chest compressions for defibrillation. WSPR Szczecin selected the device based on positive user experience following a 12-month evaluation.

The Massachusetts-based company also noted that WSPR Szczecin has initiated a program to upgrade to its new E Series Monitor/Defibrillator from the existing M Series platform.

The E Series connects directly to AutoPulse Plus, which enables real-time integrated operation of these devices, thereby allowing consistent, uninterrupted chest compressions with timed shock delivery. Chest compressions, if stopped during defibrillation, results in a rapid decline in coronary perfusion pressure. ZOLL Medical said that the integrated platform is yet to be cleared for marketing in the U.S.

The E Series provides the “Real CPR Help”, a feedback technology which helps rescuers deliver cardiopulmonary resuscitation (“CPR”) with real-time visual and audio feedback, guiding them to achieve the proper depth and rate of chest compressions.

AutoPulse Plus, an automated, portable device, offer emergency service providers an effective method of performing consistent, uninterrupted chest compressions on the victims of sudden cardiac arrest (“SCA”), improving their chances of survival. The device may offer advancement over manual chest compressions as it improves blood flow to the heart and brain during SCA. It is compliant with the European Resuscitation Council (“ERC”) guidelines.

SCA, an abrupt loss of cardiac function, is one of the major causes of unexpected deaths claiming more than 1 million lives annually worldwide. According to the American Heart Association, more than 700 people die from this condition each day in the U.S. Improved resuscitation may save as many as 50% of SCA victims.

ZOLL is a leading player in the global market for external defibrillators, which is worth more than $1 billion. To boost growth, the company is expanding its footprint in the international markets, which contribute more than 25% of its annual sales.

ZOLL Medical is the innovator of a wide range of product features that have become the standard of care in the external defibrillator industry. It remains committed to expanding its product range to sustain growth in this market. ZOLL Medical competes with Physio-Control, a wholly-owned unit of Medtronic (MDT - Analyst Report) and Philips (PHG - Analyst Report). We currently have an Outperform recommendation on the stock.

Read the full analyst report on MDT

Read the full analyst report on PHG

Read the full analyst report on ZOLL